Work

Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Plamotamab Combined with Tafasitamab (Tafa) + Lenalidomide (Len) Vs Tafa+Len in Relapsed or Refractory DLBCL

Year: 2022

Type: article

Source: Blood

DOI: 10.1182/blood-2022-158042

Authors: Krish Patel, Youngil Koh, Sabarish Ayyappan, Yasmin Karimi, Izidore S. Lossos, Akil Merchant, Phuong Lee, Jianhua Jin, Raphael Clynes, Jitendra Kanodia, Michael T. Chiarella, Steve Kye, Jean-Marie Michot

Institutions: Seoul National University, Seoul National University Hospital, University of Iowa Hospitals and Clinics, University of Michigan, Michigan Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Cedars-Sinai Medical Center, Xencor (United States), Institut Gustave Roussy

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310163543

FWCI: 0.425

Cites:

Cited by: 3

Related to: 10